Access Accelerated

Access Accelerated - a first-of-its-kind initiative to improve access to non-communicable diseases prevention, treatment and care in low and middle-income countries.

Access Accelerated is an initiative that brings together over 20 biopharmaceutical companies committed to tackling the growing burden of non-communicable diseases in low and middle-income countries. By collaborating with partners, we co-create scalable and sustainable solutions to improve people’s health.

The NCD Challenge

According to the World Health Organization, non-communicable diseases (NCDs) including cancers, cardiovascular diseases, chronic respiratory diseases, diabetes and mental health are the leading causes of death and disability worldwide. This burden is expected to rise significantly in low and middle-income countries (LMICs) in the coming decades.
Access to treatment and care for NCDs is a multidimensional challenge, with barriers spanning the entire healthcare system, from health literacy and education, screening and diagnosis, a lack of healthcare professionals and infrastructure, the provision and funding of care, and the usage of and adherence to treatment. In LMICs, the impact of these barriers is particularly profound.

Our Commitment

We are united in our shared commitment to reduce premature deaths from NCDs by one-third by 2030, by identifying-and breaking down-the barriers to prevention, treatment and care. By doing so, we are able to contribute to the achievement of the NCD target (3.4) set in the United Nations Sustainable Development Goals.

Access Accelerated aims to have a demonstrable impact on improving patient lives in LMICs by:

  • Developing a roadmap for how to treat NCDs in a sustainable way
  • Building effective partnerships to advance an enabling policy environment for health financing and service delivery for NCDs
  • Facilitating sustainable access to innovative medicines

We are:
Scaling-up individual company efforts
Member companies are committed to scaling-up existing programmes and developing new programmes to address barriers to access to prevention, treatment and care, including but not limited to:

  • Supporting health system strengthening (for example, training nurses, doctors and community health workers)
  • Preventing the growth of NCDs (for example, disease awareness raising programmes)

Collaborating with the World Bank Group

We are collaborating with the World Bank Group to establish a portfolio of integrated NCD pilot projects that can inform scale-up at the national level and serve as an entry point for innovative financing for NCDs. Through these pilot programmes, we are testing ways to improve the treatment of NCDs and strengthen health systems in LMICs.

Fostering strong, dynamic partnerships

We are forging partnerships with organisations specialising in each of the major NCD areas. In 2017 we kick-started this approach by focusing on an initial specific disease-cancer-and are partnering with the Union for International Cancer Control (UICC). As a founding member of UICC’s C/Can 2025: City Cancer Challenge, we are supporting the development of effective, sustainable cancer care delivery models in the four Key Learning Cities of Asunción, Paraguay; Cali, Colombia; Kumasi, Ghana; and Yangon, Myanmar.

ACCESS ACCELERATED AT TICAD 2019

At the Seventh Tokyo International Conference on African Development (TICAD7), Access Accelerated, in partnership with the Japan Pharmaceutical Manufacturers Association (JPMA), hosted a side event titled, "Accelerating Sustainable UHC by Improving Access to NCD Care," to explore work currently underway to increase access to non-communicable disease (NCD) care in the context of global momentum for Universal Health Coverage (UHC).

Learn More

Evaluating our impact

Through working with Boston University’s School of Public Health (BUSPH), we have developed the 'Access Observatory' and a metrics framework that measures and evaluates programmes and provides insights on how to improve programme design. Through rigorous measurement and full transparency, we are able to see and share what works, what does not and the difference our efforts are having on peoples’ lives.

Access Accelerated Members

Almirall, Astellas, Bayer, Bristol-Myers Squibb, Chiesi, Chugai, Daiichi Sankyo, Eisai, Eli Lilly and Company, IPSEN, Johnson & Johnson, Menarini, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, Servier, Shionogi, Sumitomo Dainippon, Takeda, UCB.

Associations

BIO, EFPIA, IFPMA, JPMA, PhRMA

share

TOP